Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 19Terminated 3Active not recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1Other 1Breast 1

Conditions

Obesity 1Metabolic Syndrome 1Inflammation 1Hematopoietic and Lymphatic System Neoplasm 1Dyslipidemias 1Breast Neoplasms 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Bupropion × Clear all
NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

NCT03996265 2026-01-15

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

University of Rochester

Phase 3 Active not recruiting
422 enrolled
Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

NCT05756764 2025-09-09

Anti-obesity Pharmacotherapy and Inflammation

Louisiana State University Health Sciences Center in New Orleans

Active not recruiting
30 enrolled
Other

Inflammation, Obesity, Metabolic Syndrome, Dyslipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡